Ocular manifestations of AIDS.
Clinical Branch, National Eye Institute, National Institutes of Health, Bethesda, Md 20892-1858, USA.
S M
SM
Whitcup
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use; D015774:Ganciclovir / Q000009:adverse effects / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D017828:Rifabutin / Q000009:adverse effects / Q000627:therapeutic use; D014605:Uveitis / Q000139:chemically induced / Q000150:complications; D014792:Visual Acuity
D000900:Anti-Bacterial Agents; D000998:Antiviral Agents; D017828:Rifabutin; D016049:Didanosine; D015774:Ganciclovir